EDINBURGH, July 9 (Xinhua) -- Bowel cancer patients with high levels of vitamin D in their blood are more likely to survive the disease, a study shows.
Patients with the highest levels of vitamin D have half the risk of dying compared with those with the lowest levels, said the findings of the University of Edinburgh team.
The study is the first to correlate total blood levels of vitamin D in bowel cancer patients after their diagnosis, which includes that produced after exposure to sunlight and that obtained from dietary sources, with their long term survival prospects, said the University on Wednesday.
Blood samples from almost 1,600 patients after surgery for bowel cancer had been tested, according to the study team.
The greatest benefit of vitamin D was seen in patients with stage 2 disease, at which the tumour may be quite large but the cancer has not yet spread.
Researchers found that three quarters of the patients with the highest vitamin D levels were still alive at the end of five years, compared with less than two thirds of those with the lowest levels.
The results show that vitamin D is associated with a much better chance of cancer survival, although the nature of this relationship is not clear from this study.
The study's authors aim to set up a clinical trial to test whether taking vitamin D tablets in combination with chemotherapy can improve bowel cancer survival rates.
Measuring vitamin D levels in bowel cancer patients could also provide a useful indication of prognosis, said the scientists.
"Our findings are promising but it is important to note that this is an observational study. We need carefully designed randomised clinical trials before we can confirm whether taking vitamin D supplements offers any survival benefit for bowel cancer patients," said Professor Malcolm Dunlop of the Medical Research Council Human Genetics Unit at the University of Edinburgh.
Funded by the charity Cancer Research in Britain, the research is published in the Journal of Clinical Oncology, official journal of the American Society of Clinical Oncology.